Skip to main content
Immunology logoLink to Immunology
. 1989 Dec;68(4):570–574.

Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi.

C M Black 1, D M Israelski 1, Y Suzuki 1, J S Remington 1
PMCID: PMC1385548  PMID: 2514141

Abstract

Recombinant tumor necrosis factor (rTNF) has been shown to protect mice against lethal bacterial infections. We previously reported that in in vitro experiments with mouse peritoneal macrophages, rTNF inhibited intracellular multiplication of Trypanosoma cruzi but not of Toxoplasma gondii. These disparate results led us to study the effect of rTNF on the in vivo infection with these parasites. Daily administration of 0.5 and 5.0 micrograms rTNF resulted in a dose-dependent, significantly decreased time to death (p less than 0.05) in mice infected with lethal doses of T. cruzi. The same effect was found in mice infected with T. gondii and given a daily dose of 5.0 micrograms rTNF. Lower doses of rTNF did not significantly affect time to death of mice infected with either parasite.

Full text

PDF
570

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRENER Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1962 Nov-Dec;4:389–396. [PubMed] [Google Scholar]
  2. Beutler B. A., Milsark I. W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985 Dec;135(6):3972–3977. [PubMed] [Google Scholar]
  3. Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
  4. Blanchard D. K., Djeu J. Y., Klein T. W., Friedman H., Stewart W. E., 2nd Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol. 1988 May;43(5):429–435. doi: 10.1002/jlb.43.5.429. [DOI] [PubMed] [Google Scholar]
  5. Clark I. A., Cowden W. B., Butcher G. A., Hunt N. H. Possible roles of tumor necrosis factor in the pathology of malaria. Am J Pathol. 1987 Oct;129(1):192–199. [PMC free article] [PubMed] [Google Scholar]
  6. Clark I. A., Virelizier J. L., Carswell E. A., Wood P. R. Possible importance of macrophage-derived mediators in acute malaria. Infect Immun. 1981 Jun;32(3):1058–1066. doi: 10.1128/iai.32.3.1058-1066.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. De Titto E. H., Catterall J. R., Remington J. S. Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol. 1986 Aug 15;137(4):1342–1345. [PubMed] [Google Scholar]
  8. Haidaris C. G., Haynes J. D., Meltzer M. S., Allison A. C. Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun. 1983 Oct;42(1):385–393. doi: 10.1128/iai.42.1.385-393.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hauser W. E., Jr, Sharma S. D., Remington J. S. Natural killer cells induced by acute and chronic toxoplasma infection. Cell Immunol. 1982 May 15;69(2):330–346. doi: 10.1016/0008-8749(82)90076-4. [DOI] [PubMed] [Google Scholar]
  10. Jones T. C., Alkan S., Erb P. Spleen and lymph node cell populations, in vitro cell proliferation and interferon-gamma production during the primary immune response to Toxoplasma gondii. Parasite Immunol. 1986 Nov;8(6):619–629. doi: 10.1111/j.1365-3024.1986.tb00875.x. [DOI] [PubMed] [Google Scholar]
  11. Kanbara H., Nakabayashi T. Comparative studies on trypomastigotes of Trypanosoma cruzi from infected mouse blood and infected fibroblast cell (L-cell) culture. Biken J. 1983 Mar;26(1):57–62. [PubMed] [Google Scholar]
  12. Kirstein M., Fiers W., Baglioni C. Growth inhibition and cytotoxicity of tumor necrosis factor in L929 cells is enhanced by high cell density and inhibition of mRNA synthesis. J Immunol. 1986 Oct 1;137(7):2277–2280. [PubMed] [Google Scholar]
  13. Kramer S. M., Aggarwal B. B., Eessalu T. E., McCabe S. M., Ferraiolo B. L., Figari I. S., Palladino M. A., Jr Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res. 1988 Feb 15;48(4):920–925. [PubMed] [Google Scholar]
  14. Matthews N., Ryley H. C., Neale M. L. Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization. Br J Cancer. 1980 Sep;42(3):416–422. doi: 10.1038/bjc.1980.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Parant M. Antimicrobial resistance enhancing activity of tumor necrosis serum factor induced by endotoxin in BCG-treated mice. Recent Results Cancer Res. 1980;75:213–219. doi: 10.1007/978-3-642-81491-4_33. [DOI] [PubMed] [Google Scholar]
  16. Rothstein J. L., Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A. 1988 Jan;85(2):607–611. doi: 10.1073/pnas.85.2.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rouzer C. A., Cerami A. Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol. 1980 Oct;2(1):31–38. doi: 10.1016/0166-6851(80)90046-8. [DOI] [PubMed] [Google Scholar]
  18. Taverne J., Depledge P., Playfair J. H. Differential sensitivity in vivo of lethal and nonlethal malarial parasites to endotoxin-induced serum factor. Infect Immun. 1982 Sep;37(3):927–934. doi: 10.1128/iai.37.3.927-934.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Taverne J., Dockrell H. M., Playfair J. H. Endotoxin-induced serum factor kills malarial parasites in vitro. Infect Immun. 1981 Jul;33(1):83–89. doi: 10.1128/iai.33.1.83-89.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  21. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  22. Tracey K. J., Lowry S. F., Cerami A. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis. 1988 Mar;157(3):413–420. doi: 10.1093/infdis/157.3.413. [DOI] [PubMed] [Google Scholar]
  23. Wilson C. B., Tsai V., Remington J. S. Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med. 1980 Feb 1;151(2):328–346. doi: 10.1084/jem.151.2.328. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES